JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

Kodu・Aktsiate loetelu・CorMedix Inc

CorMedix Inc

Avatud

SektorTervishoid

11.88 -2.14

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

11.81

Max

12.47

Põhinäitajad
By Trading Economics
Sissetulek	7.2M 21M
Müük	7.9M 39M
P/E Sektori keskmine	46.077 40.048
Kasumimarginaal	52.822
Töötajad	64
EBITDA	7.2M 21M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+49.31% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	13. aug 2025

Turustatistika
By TradingEconomics
Turukapital	256M 892M
Eelmine avamishind	14.02
Eelmine sulgemishind	11.88

Uudiste sentiment

By Acuity

50%

175 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bullish Evidence

9.2 / N/A Toetus ja vastupanu

CorMedix Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

4. aug 2025, 21:42 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Cabot to Acquire Mexico Carbon Manufacturing From Bridgestone

4. aug 2025, 21:21 UTC

Tulu

Suurimad hinnamuutused turgudel

Vertex Stock Falls After Pain-Drug Setback, Despite Stronger 2Q Earnings -- Update

4. aug 2025, 20:45 UTC

Tulu

Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb

4. aug 2025, 19:15 UTC

Suurimad hinnamuutused turgudel

TransMedics Group Shares Rise on FDA Approval for Clinical Trial

4. aug 2025, 23:41 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4. aug 2025, 23:41 UTC

Market Talk

Nikkei May Rise on Fed Stimulus Hopes

4. aug 2025, 23:28 UTC

Market Talk

Global Equities Roundup: Market Talk

4. aug 2025, 23:28 UTC

Market Talk

Gold Seen Stuck in Range as Investors Await Fed's Next Move -- Market Talk

4. aug 2025, 21:30 UTC

Tulu

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

4. aug 2025, 21:21 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Berkshire Stock Was Hammered Monday. It's Like 1999 Again. -- Barrons.com

4. aug 2025, 21:18 UTC

Tulu

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

4. aug 2025, 20:25 UTC

Market Talk

India Hits Back Over Russian Oil Purchases -- Market Talk

4. aug 2025, 20:25 UTC

Tulu

Transocean 2Q Loss $938M >RIG

4. aug 2025, 20:25 UTC

Tulu

Transocean 2Q Loss/Shr $1.06 >RIG

4. aug 2025, 20:18 UTC

Tulu

Palantir Stock Jumps. Earnings Blew Past Wall Street's Stratospheric Expectations. -- Barrons.com

4. aug 2025, 20:15 UTC

Tulu

Vertex Pharma: Guidance Includes Immaterial Cost Impact From Tariffs in 2025 Based on Currently Known Tariff Rates and Regulations >VRTX

4. aug 2025, 20:14 UTC

Tulu

Vertex Pharmaceuticals Reiterated FY25 Fincl Guidance >VRTX

4. aug 2025, 20:14 UTC

Tulu

Vertex Pharma: Mark Bunnage, D.Phil., SVP of Global Research, to Assume Role of CSO Effective Feb 1, 2026 >VRTX

4. aug 2025, 20:14 UTC

Tulu

Vertex Pharma: David Altshuler, Chief Scientific Officer, Intends to Retire Aug 1, 2026 >VRTX

4. aug 2025, 20:13 UTC

Tulu

Vertex Pharmaceuticals Backs FY25 Rev $11.85B-$12B >VRTX

4. aug 2025, 20:09 UTC

Tulu

Viper Energy: Initiating Avg Daily Production Guidance for 3Q of 46,000 to 49,000 Bo/d (86,000 to 92,000 Boe/d) >VNOM

4. aug 2025, 20:06 UTC

Tulu

Palantir Earnings Blow Past Wall Street's Stratospheric Expectations -- Barrons.com

4. aug 2025, 20:01 UTC

Tulu

Vertex Pharmaceuticals 2Q Net $1.03B >VRTX

4. aug 2025, 20:01 UTC

Tulu

Vertex Pharmaceuticals 2Q Adj EPS $4.52 >VRTX

4. aug 2025, 20:01 UTC

Tulu

Vertex Pharmaceuticals 2Q Rev $2.96B >VRTX

4. aug 2025, 20:01 UTC

Tulu

Vertex Pharmaceuticals 2Q EPS $3.99 >VRTX

4. aug 2025, 19:41 UTC

Market Talk

U.S. Natural Gas Futures Settle Lower -- Market Talk

4. aug 2025, 19:28 UTC

Market Talk

U.S. Hiring Expected to Recover Once Uncertainty Dissipates -- Market Talk

4. aug 2025, 19:07 UTC

Market Talk

Oil Extends Losing Streak As OPEC+ to Raise Output -- Market Talk

4. aug 2025, 18:27 UTC

Market Talk

Gold Climbs on Rate Cut Speculation -- Market Talk

Võrdlus sarnastega

Hinnamuutus

CorMedix Inc Prognoos

Hinnasiht

By TipRanks

49.31% tõus

12 kuu keskmine prognoos

Keskmine 17.38 USD 49.31%

Kõrge 20 USD

Madal 11.5 USD

Põhineb 6 Wall Streeti analüütiku instrumendi CorMedix Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

6 ratings

Osta

Hoia

Müü

Põhineb 6 analüütiku instrumendi CorMedix Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

9.2 / N/AToetus ja vastupanu

Recent bullish events outweigh bearish events.

All events are bullish.

Sentiment

By Acuity

175 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest CorMedix Inc

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.